Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.18 12.53 0.08%
S&P 500 1,881.70 6.31 0.34%
NASDAQ 4,150.38 23.41 0.57%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Photo Release -- Pacific Biosciences Launches the PacBio(R) RS II Sequencing System



Photo Release -- Pacific Biosciences Launches the PacBio(R) RS II Sequencing
System

The Gold Standard in High-Accuracy Genome Finishing Expands Into New
Applications

MENLO PARK, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- Pacific Biosciences of
California, Inc. (Nasdaq:PACB) today announced the launch of the PacBio^® RS
II – a new Single Molecule, Real-Time (SMRT^®) DNA Sequencing System that
provides the industry's highest consensus accuracy and longest read lengths,
with double the throughput from the previous version of the system.

PacBio RS II Sequencing System
 The PacBio RS II System offers a
 simple, fast, end-to-end workflow for
 SMRT Sequencing in research areas
 including infectious disease and
 microbiology, agriculture, and complex
 genetic diseases with repeat
 expansions.

A photo accompanying this release is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=18068

The PacBio RS II allows scientists to rapidly and cost effectively generate
finished genome assemblies, reveal and understand epigenomes, and characterize
genomic variation. Based on the company's revolutionary SMRT Sequencing
technology, the RS II can generate average read lengths of 5,000 base pairs,
with the longest reads above 20,000 base pairs in length. The PacBio RS II
System, including consumables and software, provides a simple, fast,
end-to-end workflow for SMRT Sequencing in research areas including infectious
disease and microbiology, agriculture, and complex genetic diseases with
repeat expansions.

With the PacBio RS II, the number of simultaneously observable sequencing
reactions is doubled, which effectively doubles the throughput of the system.
This increase in the number of reads will drive new applications such as
full-length cDNA analysis and full-length 16S metagenomics. The PacBio RS II
features PacBio's C2 and XL chemistries, new analysis software with automated
de novo assembly, and other improvements released in the past two years,
including: increased consensus accuracy to greater than 99.999% (Q50), a
quadrupling of average read lengths, and a 10-fold reduction in input DNA
required.

"In addition to providing more, high-quality data in a highly robust system,
the PacBio RS II includes all of the performance improvements we have made
since we launched the commercial PacBio RS System in 2011," said Kevin
Corcoran, Senior Vice President of Market Development. "The combined
improvements in accuracy, reliability, and throughput, as well as increased
cost efficiencies, are what many researchers have been waiting for in order to
adopt SMRT Sequencing in their laboratories."

Richard Gibbs, Ph.D., Professor and Chair of the Department of Molecular and
Human Genetics at Baylor College of Medicine and Director of the Human Genome
Sequencing Center, was among the early access users of the PacBio RS. "I have
been very impressed with the progress Pacific Biosciences has made with this
unique technology. With each performance upgrade, our ability to handle more
complex projects increases. We are now using the system to improve the
sequence of mammalian genomes."

Customers with existing PacBio RS Systems can purchase an upgrade, which will
convert the PacBio RS to the new PacBio RS II. Installations of the new PacBio
RS II System are expected to begin in the second quarter of 2013. For more
information please visit www.pacb.com/rsII.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq:PACB) offers the PacBio^® RS
II Sequencing System to help scientists solve genetically complex problems.
Based on its novel Single Molecule, Real-Time (SMRT^®) Sequencing technology,
the company's products enable: targeted sequencing to more comprehensively
characterize genetic variations; de novo genome assembly to more fully
identify, annotate and decipher genomic structures; and DNA base modification
identification to help characterize epigenetic regulation and DNA damage. By
providing access to information that was previously inaccessible, Pacific
Biosciences enables scientists to increase their understanding of biological
systems.

The photo is also available via AP PhotoExpress.

CONTACT: Media:
         Maurissa Messier
         For Pacific Biosciences
         760.539.7417
         maurissa@bioscribe.com
        
         Investors:
         Trevin Rard
         Pacific Biosciences
         650.521.8450
         ir@pacificbiosciences.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement